Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03744676
Title A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Juno Therapeutics, a Subsidiary of Celgene

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma

non-Hodgkin lymphoma


Lisocabtagene maraleucel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.